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Key Points 
- While several studies have investigated the effects of exercise training in human 
skeletal muscle and the chronic effect of β2-agonist treatment in rodent muscle, their 
effects on muscle proteome signature with related functional measures in humans are 
incomplete 
- Herein we show that daily β2-agonist treatment attenuates training-induced 
enhancements in exercise performance and maximal oxygen consumption, and alters 
muscle proteome signature and phenotype in trained young men 
- Daily β2-agonist treatment abolished several of the training-induced enhancements in 
muscle oxidative capacity and caused a repression of muscle metabolic pathways. 
Furthermore, β2-agonist treatment induced a slow-to-fast twitch muscle phenotype 
transition 
- The present study indicates that chronic β2-agonist treatment confounds the positive 
effect of high intensity training on exercise performance and oxidative capacity, 
which is of interest for the large proportion of persons using inhaled β2-agonists on a 
daily basis, including athletes 
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Abstract 
Although the effects of training have been studied for decades, data on muscle proteome 
signature remodelling induced by high intensity training in relation to functional changes in 
humans remains incomplete.  Likewise, β2-agonists are frequently used to counteract 
exercise-induced bronchoconstriction, but the effects β2-agonist treatment on muscle 
remodelling and adaptations to training are unknown. In a placebo-controlled parallel study, 
we randomized 21 trained men to four weeks of high intensity training with (HIT+β2A) or 
without (HIT) daily inhalation of β2-agonist (terbutaline, 4 mg/d). Of 486 proteins identified 
by mass-spectrometry proteomics of muscle biopsies sampled before and after the 
intervention, 32 and 85 were changing (FDR≤5%) with the intervention in HIT and 
HIT+β2A. Proteome signature changes were different in HIT and HIT+β2A (p=0.005), 
wherein β2-agonist caused a repression of 25 proteins in HIT+β2A compared to HIT, and an 
upregulation of 7 proteins compared to HIT. β2-agonist repressed or even downregulated 
training-induced enrichment of pathways related to oxidative phosphorylation and glycogen 
metabolism, but upregulated pathways related to histone trimethylation and the nucleosome.  
Muscle contractile phenotype changed differently in HIT and HIT+β2A (p≤0.001), with a 
fast-to-slow twitch transition in HIT and a slow-to-fast twitch transition in HIT+β2A. β2-
agonist attenuated training-induced enhancements in maximal oxygen consumption (p≤0.01) 
and exercise performance (11.6 vs. 6.1%, p≤0.05) in HIT+β2A compared to HIT. These 
findings indicate that daily β2-agonist treatment attenuates the beneficial effects of high 
intensity training on exercise performance and oxidative capacity, and causes remodelling of 
muscle proteome signature towards a fast-twitch phenotype.  
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ABBREVIATIONS 
ATP; adenosine triphosphate, β2-agonist; beta2-adrenoceptor agonist, cAMP; cyclic 
adenosine monophosphate, CSA; cross-sectional area, HIT; High intensity training + placebo 
group, HIT+β2A; High intensity training + β2-agonist group), MHC; myosin heavy chain, 
PKA; protein kinase A, TCA; tricarboxylic acid cycle,  ̇     ; maximal oxygen 
consumption. 
 
Background 
Exercise is essential for maintaining physical function and health, and is positively related to 
quality-of-life and life expectancy (Westerterp, 2001; Dhana et al. 2016). Thus, exercise is 
considered one of the best non-pharmacological strategies to prevent and even reverse several 
pathological conditions (Goodyear, 2008). In addition, exercise training is crucial for optimal 
performance in the vast majority of sport disciplines. High intensity training is widely 
practised because of its superior efficacy in improving physiological measures compared to 
low- and moderate intensity exercise (Milanovic et al. 2015). Only a few weeks of high 
intensity training improves cardiovascular fitness and induces several beneficial adaptations 
in skeletal muscle (Laursen & Jenkins, 2002; Hostrup & Bangsbo, 2017). The adaptations 
induced by high intensity training are related to major cellular perturbations in skeletal 
muscle that activate a variety of signalling pathways and gene programs (Arany et al. 2008; 
Canto et al. 2009; Powers et al. 2010; Hoffman et al. 2015; Brandt et al. 2016). However, 
while considerable progress has been made in understanding myocellular adaptations induced 
by training (Egan et al. 2011; Petriz et al. 2012; Hawley et al. 2014; Murton et al. 2014; 
Padrão et al. 2016; Powers et al. 2016; Sollanek et al. 2017), only few studies have 
investigated the effect of high intensity interval training on muscle proteome signature 
changes (Holloway et al. 2009; Egan et al. 2011; Hussey et al. 2012) and integrated such 
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changes with adaptations in muscle phenotype, contractile function and exercise performance 
in humans (Petriz et al. 2012; Padrão et al. 2016). Integrated approaches are needed to 
provide a global perspective on the relation between muscle remodelling and functional 
changes induced by training from a basic physiological standpoint and for future therapeutic 
applications. 
 
A large proportion of the population experiences respiratory complications during physically 
demanding activities (Price et al. 2014). A common cause of this problem is asthma and 
exercise-induced bronchoconstriction with a prevalence of around 10% in Western countries 
(Cruz, 2007; Kainu et al. 2013). Inhaled β2-adrenoceptor agonists (β2-agonists) are used as 
first-line treatment of the bronchoconstriction associated with asthma and exercise-induced 
bronchoconstriction, and are as such among the most commonly prescribed medications 
worldwide (Rottenkolber et al. 2015). While the main application of inhaled β2-agonists is to 
induce bronchodilation, a large proportion of the drug enters the systemic circulation and 
distributes to all organs (Jacobson et al. 2014; Dyreborg et al. 2016). The largest organ of the 
body, skeletal muscle, contains a high density of β2-adrenoceptors (Williams et al. 1984; 
Jensen et al. 2002) that serve an important role in the adrenergic fight-or-flight response 
(Jensen et al. 2008; Emrick et al. 2010; Andersson et al. 2012; Hostrup et al. 2014a). Thus, 
acute inhalation of β2-agonist has been shown to affect ion handling and energy production of 
skeletal muscle in trained young men (Hostrup et al. 2014a; Kalsen et al. 2016a; 2016b). 
Furthermore, when administered chronically, β2-agonists induce hypertrophy and alter 
metabolic and contractile properties of skeletal muscle (Martineau et al. 1992; Dodd et al. 
1996; Rajab et al. 2000; Hostrup et al. 2015). Therefore, β2-agonists have been proposed as 
therapeutic agents to combat lifestyle-related diseases, muscle dysfunction and age-related 
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muscle atrophy (Lynch & Ryall, 2008; Joassard et al. 2013). However, despite their 
widespread use, it is unknown what effect daily inhalation of β2-agonist has on training-
induced adaptations in skeletal muscle and functional capacity in humans. This is important, 
since inhaled β2-agonists are often used in conjunction with physical activity in persons with 
asthma and exercise-induced bronchoconstriction (Arie, 2012; Price et al. 2014). For 
instance, in some sports, as many as 50% of athletes use inhaled β2-agonists in conjunction 
with training and competition (Parsons & Mastronarde, 2005). A better understanding of 
these β2-agonist mediated effects on muscle proteome and phenotype could lead to improved 
treatment modalities in a diverse range of diseases such as muscle wasting and obesity. 
 
Thus, the purpose of the present study was to investigate proteome signature and phenotype 
changes of skeletal muscle induced by high intensity training with and without concomitant 
daily treatment with β2-agonist in therapeutic doses, integrating muscle remodeling with 
relevant functional measures related to maximal oxygen consumption ( ̇     ), exercise 
performance and muscle contractile properties in trained young men. We hypothesised that 
daily β2-agonist treatment would alter training-induced modulation of muscle proteome 
signature and cause a shift towards a fast-twitch muscle phenotype.  
 
Methods 
Human subjects and ethics 
Twenty-four healthy trained men were initially screened of which 21 were included in the 
study. Prior to inclusion, subjects received oral and written information about the aims and 
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contents of the study as well as possible risks involved, including side effects associated with 
the study drug (terbutaline). Each subject gave his oral and written informed consent. A 
physician screened each subject for unknown cardiopulmonary disease with lung and heart 
auscultation and electrocardiography. Inclusion criteria were males, aged 18 to 40 years, 
informed consent, a weekly training volume of 2-5 h and a body mass index between 19 and 
25 kg/m
2
.  Exclusion criteria were smoking, allergy towards study drug, and chronic disease. 
Subjects were recreationally active, engaging in team sports, running, biking and/or light 
resistance training. Subjects were told to refrain from competitive events for the entire study 
and not to change their daily physical activities and nutritional habits, which were recorded. 
The study was conducted in accordance with the standards set by the 2013 version of the 
Declaration of Helsinki and was approved by the regional research ethics committee of 
Copenhagen, Denmark (H-4-2014-002). The study was registered in ClinicalTrials.gov 
(NCT02557581). 
 
Study design 
The study was designed as a block-randomized controlled parallel study with two groups: 
Either four weeks of high intensity training and daily inhalation of placebo (HIT, n = 9) or 
four weeks of high intensity training and daily inhalation of terbutaline (HIT+β2A, n = 12). 
Upon inclusion, subjects were randomly allocated in the two groups, stratified for  ̇      
and lean body mass. In HIT, subjects received a placebo inhalator (Turbohaler, AstraZeneca, 
Cambridge, UK) and in HIT+β2A subjects received an inhalator of the selective β2-agonist 
terbutaline (Bricanyl® Turbohaler 0.5 mg/dose, AstraZeneca, Cambridge, UK). Subjects 
were instructed to inhale eight doses once daily for 28 ± 1 days. 
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Study drugs 
Terbutaline is a commonly prescribed short-acting β2-agonist in Northern Europe, which has 
a high selectivity for the β2-adrenoceptor (Baker, 2010) and a half-life of ~4 h (Krogh et al. 
2017). The dosage of inhaled terbutaline administered (8×0.5 mg) in the present study is 
higher than that normally prescribed to asthmatics (Bricanyl® Turbohaler, product 
information, www.astrazeneca.com), but equivalent to the daily upper limit for inhaled 
salbutamol in competitive sports (2017 list of prohibited substances, www.wada-ama.org). 
The rationale for the dosage of 4 mg was to ensure an adequate systemic response, while 
staying within the current upper therapeutic limit in competitive sports. Systemic 
concentrations of terbutaline after inhalation of 4 mg have been shown to reach their peak 
within ½-1 h with concentrations of ~5-8 ng/mL (Dyreborg et al. 2016; Kreiberg et al. 2017). 
Such concentrations are equivalent or even higher than those observed after oral 
administration of 10 mg terbutaline (Elers et al. 2012; Dyreborg et al. 2016). To ensure a 
drug compliance of 100%, inhalations were monitored by study staff on a daily basis via 
online video tools (FaceTime/Skype). Because β2-agonists may affect energy turnover and 
ion handling in skeletal muscle (Kalsen et al. 2014; Hostrup et al. 2014a; Hostrup et al. 
2014b; Kalsen et al. 2016a), subjects inhaled their daily dose after exercise sessions at days 
of training. During non-training days, subjects inhaled their daily dose in the time frame of 
9:00-18:00. The duration of treatment was based on a previous study showing that four weeks 
of treatment with terbutaline leads to adaptations in skeletal muscle of humans (Hostrup et al. 
2015). Both subjects and investigators were blinded against treatment. Terbutaline 
Turbohalers were delivered by the regional pharmacy of Copenhagen, Denmark. Placebo 
Turbohalers were kindly delivered by AstraZeneca. Randomization was conducted in SPSS 
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(IBM, Armonk, NY, US) by staff that did not take part in any of the experimental procedures 
or data analysis. 
 
Experimental protocol 
Before the start of the intervention, subjects attended two trials at the laboratory separated by 
two days. At the first trial, subjects’ thigh lean mass was determined by Dual-energy X-ray 
absorptiometry (DXA)(Lunar iDXA, GE Healthcase, Belgium). Subjects were placed in the 
scanner in supine position undressed. All DXA scans were performed with 10 min of supine 
rest before scanning to allow distribution of body fluids. To reduce intra-day variation, two 
scans were performed. After the scans, subjects rested in a supine position for 20 min and 
resting metabolic rate was determined by indirect calorimetry breath-by-breath with a gas 
analyzer system (Oxycon Pro, CareFusion, San Diego, CA, US) for 15 min. Subjects then 
performed a standardized warm-up on a bike ergometer at 100 W for 10 min (Monark LC4, 
Monark Exercise AB, Vansbro, Sweden). After warm-up, subjects’ contractile properties of 
the quadriceps muscle were assessed by maximal voluntary contraction (MVC). After MVC, 
subjects’  ̇      and performance were determined during incremental cycling to exhaustion 
on the bike ergometer starting with 4 min of cycling at 100 W, in which substrate utilization 
was determined by indirect calorimetry as described by Jeukendrup & Wallis (2005), 
followed by 4 min at 150 W and 200 W, after which workload increased by 30 W every min 
until exhaustion. 
 
At the second trial, thigh lean mass and resting metabolic rate were determined similar to the 
first trial to minimize day-to-day variation. Afterwards, subjects warmed up on the bike 
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ergometer for 4 min, followed by cycling at a workload corresponding to 60% of subjects’ 
 ̇      for determination of substrate utilization at same relative intensity of  ̇     . After 
the exercise, subjects’ contractile properties of the quadriceps muscle were measured as 
performed during the first trial to minimize day-to-day variation. Subjects then rested for 30 
min and had a muscle biopsy taken from the vastus lateralis of the right thigh using a 
Bergstrøm needle with suction (Bergstrøm, 1975). Prior to biopsy sampling, an incision (3 
mm) was made through the skin and fascia at the vastus lateralis belly under local anesthesia 
(2 mL lidocaine without epinephrine, 20 mg/mL Xylocain®, AstraZeneca, Cambridge, UK). 
After the second trial, subjects received either placebo or terbutaline according to their group. 
 
Upon conclusion of the four-week intervention, subjects reported to two similar laboratory 
trials as the ones conducted before the intervention. To ensure complete washout of 
terbutaline (half-life ~4 h)(Krogh et al. 2017), post-testing was performed 2-3 days after last 
inhalation.  
 
Subjects were told to abstain from caffeine, strenuous exercise and alcohol 48 h before each 
laboratory trial. To minimize variation, subjects ingested a standardized meal and fluid 1½ h 
before the laboratory trials. 
Training intervention 
During the four-week intervention, subjects performed a high intensity-training programme 
of 3 sessions pr. week on indoor spinning bikes. Each training session was supervised by an 
instructor and consisted of a standardised 10 min warm-up followed by three blocks of 
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exercise at ≈85% of maximum heart rate for 10 min with 30 s of all-out sprinting at the end 
of each 10 min block. Repeated all-out sprints of 30 s were chosen, as studies have shown 
that this type of training effectively induces adaptations in skeletal muscle (Hostrup & 
Bangsbo, 2017). During each training session, subjects wore heart rate monitors that fed 
subjects’ heart rate to the instructor’s iPad (iPad 4, Apple Inc., California, US) using Polar 
Team app (Polar Electro Denmark, Holte, Denmark), thus ensuring that subjects kept their 
target heart rate. Training adherence was 100% for all subjects, apart from one subject who 
missed one training session during the four-week intervention. 
 
Experimental procedures 
Contractile properties of the quadriceps muscle 
Subjects’ contractile properties of the quadriceps muscle were determined during MVC with 
percutaneous electrical muscle stimulation during and immediately after each contraction as 
described previously (Hostrup et al. 2015). Subjects were familiarized with two 3-4 s 
submaximal isometric muscle contraction at 40 and 70 % of MVC and with constant current 
electrostimulation, (Digitimer, model DS7AH, Welwyn garden city, England) at 100, 400, 
700 and 999 mA with 400 V for 200 μs, before the first MVC. The electrostimulation used 
could activate 42.6 (± 3.3)% of subjects’ peak MVC. Each MVC consisted of a 3-4 s 
maximal contraction with verbal encouragement. A potentiated twitch was applied when 
subjects reached their apparent peak MVC, as well as 1 s following relaxation. Peak twitch 
torque, time-to-peak twitch torque, half-relaxation time and voluntary activation level were 
calculated as previously described (Bachasson et al. 2013). Rate of force development was 
calculated as the average slope on the moment-time curve at the time interval 0-200 ms 
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relative to the onset of muscle contraction during MVC (Aagaard et al. 2002). Onset of 
muscle contraction was defined as the time point at which the moment curve increased to 
values above 2.5% of the magnitude of the moment achieved during MVC.  
 
For each variable, a grand mean was calculated from the average of the two highest values 
from both trials. The distance from the base of patella to the middle of the Velcro strap on the 
ankle was registered and used to calculate torque in Newton meter (Nm). 
 
Muscle biopsies 
Sampled biopsies were divided in two pieces of which the first piece (20-30 mg) was 
mounted on an embedded medium (OCT Compound Tissue-Tek; Sakura Finetek, 
Zoeterwoude, The Netherlands), frozen in isopentane cooled to the freezing point in liquid 
nitrogen, and stored at -80°C until analysis for fiber type distribution, capillaries and fiber 
cross-sectional area by immunohistochemical analysis. The other biopsy piece (50-100 mg) 
was washed in ice-cold saline to reduce blood contamination, then dried and frozen in liquid 
nitrogen, and stored in cryo tubes for later proteomic, enzymatic and Western blot analyses. 
Prior to these analyses, each biopsy was freeze-dried and dissected free from apparent non-
muscle tissue. The dissected muscle tissue was then divided in three pieces for proteomics (≈ 
10 mgdw), Western blotting (≈ 1.5 mgdw) and enzyme activity assays (≈ 2 mgdw). Because of 
inadequate muscle tissue yield from one subject in HIT, only proteomic analysis was 
performed for this subject. 
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Mass spectrometry proteomics  
Proteins were extracted from muscle biopsies using two-step sequential extraction as 
described previously (Wilson et al. 2010; Nuez-Ortin et al. 2016; 2017). Proteins were 
extracted in progressively denaturing buffers (150 mM NaCl, 50 mM Tris, pH 8.0 followed 
by 7 M urea, 2 M thiourea, 50 mM Tris, pH 8.0), and 100 µg of protein sample was reduced 
using 10 mM DTT (overnight at 4 degrees), alkylated using 50 mM iodoacetamide (2 h at 
ambient temperature in the dark) then trypsin digested by co-precipitation.  Briefly, 1 µg 
trypsin was spotted onto the wall of each sample Eppendorf tube then flushed into the sample 
with 1 mL 100% methanol chilled to -20 degrees. Samples were kept at -20 degrees overnight 
to allow co-precipitation of proteins with trypsin, then centrifuged in a benchtop 
microcentrifuge (5 min at 12,000×g) and pellets allowed to air-dry for 10 min. After addition 
of 100 mM ammonium bicarbonate, samples were then incubated for 5 h at 37 degrees with 
the further addition of 1 µg trypsin after 3 h. Samples were acidified by the addition of 1% 
formic acid and non-digested protein removed by centrifugation in a benchtop 
microcentrifuge (5 min at 12,000×g). Protein concentrations were estimated by Bradford 
assay (Bio-Rad) and 100 g aliquots of each sample were cleaned up using ethanol 
precipitation (9:1 v/v ethanol:protein).  Protein samples were trypsin digested at a ratio of 
50:1 protein:trypsin using established methods (Wilson et al. 2010) and 1 g aliquots of each 
peptide sample were analysed using an LTQ-Orbitrap and Ultimate 3000 nano RSLC system 
(Thermo Fisher Scientific, MA, USA) using published methods for separation and data-
dependent acquisition (Wilson et al. 2016).  
This method has been shown to be an effective approach to sample fractionation in complex 
and challenging tissues rich in structural proteins, such as cartilage (Wilson et al. 2010), 
whole fish larvae (Nuez-Ortin et al. 2016) and in white muscle (Nuez-Ortin et al. 2017) and 
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skeletal muscle (Barbé et al. 2017).  Prior to processing the complete set of samples, a subset 
of six tissue biopsies was used to evaluate the extraction method for human skeletal muscle 
proteomics.  Comparison of the extracted proteins indicated clear separation of the contractile 
proteins (e.g. actin, myosin and troponin) from readily soluble cytosolic proteins (e.g. 
glutathione S-transferases, 14-3-3 proteins and carbonic anhydrases) demonstrating the value 
of this approach to reduce sample complexity at the protein level.    
 
Protein identification and data processing 
Data files were imported into MaxQuant version 1.5.1.2 (http://maxquant.org/), where 
sequential extracts were defined as fractions of the same biological sample, and MS/MS 
spectra were searched against the Swiss-Prot Human reference proteome database 
(downloaded 18/03/2016; 20,1015 entries) using the Andromeda search engine. Default 
settings for protein identification by LTQ-Orbitrap MS/MS and label-free quantitation (LFQ) 
included a maximum of two missed cleavages, mass error tolerances of 20 ppm then 4.5 ppm 
for initial and main peptide searches, respectively, 0.5 Da tolerance for fragment ions, 
variable methionine oxidation and fixed cysteine carbamidomethylation. A false discovery 
rate of 1% was used for both peptide-spectrum matching and protein identification. The LFQ 
protein intensity values were extracted from the MaxQuant proteinGroups.txt file into 
Perseus software (http://perseus-framework.org/), filtered to remove proteins identified by 
reverse database matching and on the basis of modified peptides only and then log2-
transformed. Proteins detected in fewer than twelve biological samples were also excluded 
and remaining missing values were imputed using low-abundance LFQ intensity values 
drawn from a normal distribution, according to default values in Perseus. In total, 9932 
unique peptides were identified matching 783 proteins. Prior to statistical comparative 
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analysis, protein data were filtered for potential non-skeletal muscle contamination using the 
Human Protein Atlas (Uhlén et al. 2015; Thul et al. 2017). In accordance with the Human 
Protein Atlas (June 2017), 297 were determined not to be expressed at a protein level in 
skeletal muscle and were not included in further statistical analysis. The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 
partner repository with the dataset identifier PXD005480.  
 
Immunohistochemistry and confocal imaging 
Muscle fiber type distribution, capillaries and fiber cross-sectional area were determined by 
immunohistochemistry and confocal imaging as described previously (Nyberg et al. 2016). 
Briefly, the embedded muscle samples were cut in transverse sections of 8 μm in a cryostat. 
Sections were fixed for 2 min in phosphate buffered saline (PBS, pH 7.2, Gibco 70013-016, 
Life Technologies Denmark, Nærum, Denmark) containing 2% formaldehyde and washed in 
a 1:10 wash buffer (Dako S3006, Glostrup, Denmark), and blocked for 10 min in PBS 
containing 1% BSA for immunohistochemical staining. Antibodies were diluted in antibody 
diluent (Dako S0809). First, capillaries and myofiber type IIA were visualized using 
biotinylated Ulex europaeus agglutinin I lectin (1:100; VECTB- 1065, VWR, Bie and 
Berntsen, Herlev, Denmark) and a monoclonal antibody (1:200; SC-71, Hybridoma Bank, 
Iowa City, IA), respectively. Second, myofiber borders were visualized using an antibody 
against laminin (1:500; Dako Z0097) together with myosin heavy chain (1:1000; Sigma-
Aldrich Denmark M8421, Brøndby, Denmark) added for distinction of myofiber type I. 
Specific secondary antibodies [order listed: Streptavidin/FITC, (1:200; DAKO F0422), 
Alexa- 555 donkey anti-mouse (1:1000; Invitrogen A31570, Life Technologies Denmark), 
Alexa-350 goat anti-rabbit (1:1000; Invitrogen P10994) and Alexa-488 donkey anti-mouse 
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(1:1000; Invitrogen A21202)] were applied to each primary antibody. Three individual 
muscle fiber types were identified as type I (green), type IIA (red), and type IIX 
(unstained/black). Visualization was performed on a computer screen using a light 
microscope (Carl Zeiss, Germany), and all morphometric analysis were performed using a 
digital analysis program (ImageJ, NIH ImageJ). Two or more separate sections of a cross-
section were used for analysis, and the cross-sectional area was assessed by manually 
drawing the perimeter around each selected section. The number of muscle fibers and 
capillaries within each section was counted, and capillary supply was subsequently expressed 
as capillaries per fiber (capillary-to-fibre ratio) and capillary density (cap/mm
2
). Mean fiber 
area was assessed by manual drawing of the perimeter of each muscle fiber. All analyses 
were carried out manually by the same blinded investigator. 
 
Immunoblotting and SDS page 
Protein expression by Western blotting were determined as previously described (Thomassen 
et al. 2010). Protein concentration of each sample was determined with a BSA kit 
(ThermoFisher Scientific, MA, US). Samples were mixed with 6×Laemmli buffer (7 ml 0.5 
M Tris-base, 3 ml glycerol, 0.93 g DTT, 1 g SDS and 1.2 mg bromophenol blue) and ddH2O 
to reach equal protein concentration. Equal amount of protein was loaded in each well of pre-
casted gels (Bio-Rad Laboratories, CA, US). Samples from each subject were loaded on the 
same gel with a mixed human muscle standard lysate loaded in two different wells used for 
normalization. Bands were visualised with ECL (Millipore, MA, US) and recorded with a 
digital camera (ChemiDoc MP Imaging System, Bio-Rad Laboratories, CA, US). 
Densitometry quantification of band intensity was done using Image Lab version 4.0 (Bio-
Rad Laboratories, CA, US) and determined as the total band intensity adjusted for 
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background intensity. Primary antibodies used were citrate synthase (#ab96600, Abcam, MA, 
US), GLUT4 (#PA1-1065, ThermoFisher Scientific, MA, US), glycogen synthase 
(GS)(#3893, Cell Signalling Technology, MA, US), OXPHOS (#ab110411, Abcam, MA, 
US) and phosphofructokinase (Sc-166722, Santa Cruz Biotechnology, Inc, Dallas, US). The 
secondary antibodies used were HRP conjugated rabbit anti-sheep (P-0163), goat anti-mouse 
(P-0447, DAKO, Denmark) and goat anti-rabbit IgM/IgG (4010-05 Southern Biotech, AL, 
US).  
 
Enzymatic activity  
Maximal enzyme activity of citrate synthase, hexokinase, phosphofructokinase, and lactate 
dehydrogenase was quantified in muscle homogenates using fluorometric methods 
(Fluoroscan Ascent, Thermo Scientific, Waltham, MA) as described by Lowry & Passonneau 
(1972). 
 
Statistics 
Statistical analyses were performed in SPSS version 24. Sample size was based on previous 
studies of terbutaline (Hostrup et al. 2015; Dyreborg et al. 2016). Data were tested for 
normality using the Shapiro Wilks test and Q-Q plots. Data were normally distributed and 
magnitudes of outcome statistics are presented as means (± 95% confidence interval) and p-
values to represent probability. To estimate within- and between-group changes with the 
intervention, two-tailed linear mixed modelling was used with group and trial included as 
fixed factors and a random factor for subjects for a full factorial design. Age was included as 
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a time-invariant covariate in the mixed model, since age has been shown to influence the 
response to β2-agonists (White et al. 1994). For univariate correlation analyses, Pearson 
product-moment correlation coefficient was used. For the proteomic data, a series of mixed 
models were performed on the log2 expression for each protein to estimate protein-specific 
within- and between-group changes with the intervention. The false discovery rate (FDR) 
method as described by Storey & Tibshirani (2003) was used to control for multiple testing. 
Differently expressed proteins (FDR ≤ 5%) were subjected to functional annotation 
enrichment analysis (David Bioinformatics resources 6.8, NIH, US) based on gene ontology 
(GO) terms biological processes (GO:BP) and cellular components (GO:CC) as well as 
KEGG terms using an EASE score threshold of 0.1 and the Benjamini-Hochberg procedure 
to adjust p-values. Linear discriminant analysis-principal component analysis with varimax 
rotation was used to estimate between-group separation in the muscle proteome, only 
including the first eight principal components in the discriminant analysis because of the 
sample size of nine in HIT.  
 
Results 
Muscle proteome remodelling 
Of the 486 proteins identified as human skeletal muscle proteins, training upregulated 
expression of 26 proteins (Table 2) and downregulated expression of 6 proteins (Table 3) in 
HIT (FDR ≤ 5%)(Fig. 1a), whereas concomitant daily inhalation of β2-agonist upregulated 
expression of 34 proteins (Table 4) and downregulated expression of 51 proteins (Table 5) in 
HIT+β2A (Fig. 1b). Inhalation of β2-agonist caused a repression of 25 proteins in HIT+β2A 
compared to HIT (group by trial interaction), and an upregulation of 7 proteins compared to 
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HIT (Table 6)(Fig. 1c). Proteome signature changes induced by the intervention in HIT and 
HIT+β2A were markedly different as indicated by a clear separation of the two groups 
(Wilks’ Lambda: 0.228, p = 0.005) in a principal component-discriminant analysis that 
explained 70% of total proteome variance (Fig. 1d). 
 
Functional annotation enrichment analysis of differently expressed proteins (FDR ≤ 5%) 
based on gene ontology (GO) terms biological processes (GO:BP), cellular components 
(GO:CC) and KEGG pathways revealed different enrichments induced by the intervention in 
HIT and HIT+β2A (Fig. 1e-g). In HIT, the most dominantly upregulated pathways were 
related to the mitochondria, in particular the oxidative phosphorylation, as well as metabolic 
pathways, including glycogen metabolism (Fig. 1e). In contrast, HIT+β2A predominantly had 
an upregulation of pathways related to the cytosol, metabolism and cell-to-cell adhesion (Fig. 
1f). HIT had a minor downregulation of pathways related to myosin filaments, protein 
kinases and the cytosol (Fig. 1e), whereas HIT+β2A had several downregulated pathways, 
including those related to the cytosol and metabolism, including pyruvate and amino acid 
metabolism (Fig. 1f). Between-group analysis revealed that daily inhalation of β2-agonist 
downregulated pathways related to glycogen metabolism and oxidative phosphorylation in 
HIT+β2A compared to HIT, but upregulated pathways related to histone trimethylation and 
the nucleosome (Fig. 1g).  
 
β2-agonist blunts training-induced enhancements in  ̇      and exercise performance 
A key observation was that inhalation of β2-agonist completely blunted (p ≤ 0.01) training-
induced improvement in  ̇      and reduced (p ≤ 0.05) enhancement in exercise 
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performance during incremental cycling to exhaustion (Fig. 2b). While training effectively 
augmented  ̇      in HIT (p ≤ 0.01), HIT+β2A had no relevant changes in  ̇      with the 
intervention (Fig. 2b). Furthermore, HIT had a two-fold greater enhancement in exercise 
performance compared to HIT+β2A (11.6 vs. 6.1%, p ≤ 0.05)(Fig. 2b). Between-group 
changes in  ̇      were still evident after adjusting for adaptations in resting metabolic rate 
and thigh lean mass (Fig. 2c), which indicates that the increase in  ̇      observed in HIT 
and the attenuating effect of β2-agonist observed in HIT+β2A were attributed to other factors 
than different adaptations in resting metabolic rate and hypertrophy of the exercising 
muscles. For training-induced enhancement in exercise performance, the between-group 
difference was also evident after adjusting for thigh lean mass (Fig. 2c). On the other hand, 
when adjusting for change in  ̇     , no differences were observed in training-induced 
enhancement in exercise performance between the groups, thus indicating that the blunting 
effect of β2-agonist on training-induced enhancement in performance in HIT+β2A was related 
to the attenuating effect of β2-agonist on improvement in   ̇     .  
 
Muscle capillary density has been shown to be related to  ̇      and associated with 
endurance performance (Saltin et al. 1977; Coyle et al. 1991). Nonetheless, we observed 
opposite adaptations in capillarisation of the vastus lateralis muscle considering that observed 
for  ̇      and exercise performance. Inhalation of β2-agonist increased capillary density by 
13% (p ≤ 0.05) and capillary-to-fibre ratio by 21% (p ≤ 0.01) in HIT+β2A, whereas HIT had 
no relevant changes with the intervention (Fig. 2d). Thus, the increased  ̇      in HIT and 
blunted effect in HIT+β2A might be related to an inhibitory effect of β2-agonist on 
adaptations of the heart or mitochondrial oxidative capacity of the exercised muscles 
(Holloszy et al. 1984).  
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From proteomic analysis, we detected and grouped 13 proteins related to the tricarboxylic 
acid (TCA) cycle and 58 proteins related to oxidative phosphorylation of the mitochondria 
(Fig. 2a). For the TCA cycle, only minor changes were observed, in which succinate 
dehydrogenase flavoprotein subunit increased in both groups (Table 2+4), whereas aconitate 
hydratase and malate dehydrogenase decreased in HIT+β2A (Table 5) with a between-group 
interaction for aconitate hydratase (Table 6). While proteomic analysis revealed no 
significant changes in citrate synthase, Western blotting showed a minor increase in HIT with 
a tendency towards a higher maximal enzymatic activity (Fig. 2f), but not statistically 
different from HIT+β2A. There was a good correlation between the proteomic measurements 
of citrate synthase with that of Western blotting and enzymatic activity (Fig. 2g). In the 
oxidative phosphorylation, pronounced modulation was observed with the intervention. In 
HIT, abundance of a variety of the NADH dehydrogenase subcomplexes and ATP synthase 
subunits increased with the intervention (Table 2), whereas HIT+β2A only had few 
significantly upregulated proteins (Table 4) and even blunted training-induced increase in 
abundance of four NADH dehydrogenase subcomplexes (Table 6). Consistent with this 
finding, Western blotting revealed an upregulation of overall abundance of OXPHOS 
complexes I-V in HIT (p ≤ 0.01), whereas this effect was attenuated (p ≤ 0.01) in HIT+β2A 
(Fig. 2h).  
 
β2-agonist alters contractile phenotype 
Some clearly distinct adaptations in muscle contractile properties and phenotype were 
observed between the groups. As shown in Fig. 3a+b, muscle proteome signature changed 
differently in HIT and HIT+β2A as indicated by a between-group separation (Wilks’ Lambda: 
0.127, p ≤ 0.001)(Fig. 3b) in a principal component-discriminant analysis that explained 80% 
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of the variance for the contractile proteins listed in Fig. 3a. These between-group differences 
were primarily driven by opposing adaptations in myosin light chains, troponin C and 
tropomyosin alpha and beta chains (Table 6), all of which may affect contractile properties 
and myofibrillar Ca
2+
 sensitivity (Greaser et al. 1988; Lamboley et al. 2014). Muscle fibre 
phenotype has historically been categorised according to MHC isoforms (Lutz et al. 1979; 
Harridge et al. 1996). Expression of myosin 1, the most highly expressed myosin isoform in 
type IIx fibres (Murgia et al. 2015), decreased with the intervention in HIT (log2-fold change: 
-0.48, p ≤ 0.05)(Fig. 3a+Table 2). Consistent with this observation, immunohistochemical 
analysis of the muscle biopsies revealed significant between-group changes (p ≤ 0.05) with 
the intervention, in which HIT had a reduction in distribution of MHCIIx (p ≤ 0.05)(Fig. 3c), 
whereas HIT+β2A had an increase in distribution of MHCIIa by 4.1% (p ≤ 0.05) (Fig. 3c). 
There was a high degree of consistency between myosin expression data determined by 
proteomics and MHC isoform distribution determined immunohistochemically (Fig. 3d). 
Aside from muscle contractile phenotype changes, HIT and HIT+β2A had some different 
adaptations in sarcomere architecture and cell-to-cell adhesion. Compared to HIT, HIT+β2A 
had an upregulation of actin- and anchoring related proteins actin and alpha-actinin-1 (Table 
6). 
 
Although a common effect of β2-agonist treatment is muscle growth (Lynch & Ryall, 2008; 
Joassard et al. 2013; Hostrup et al. 2015), we observed a similar degree of thigh muscle 
hypertrophy in both groups with the intervention (Fig. 3f). At the muscle fibre level, 
however, histochemical analysis revealed that only HIT had an increase in mean cross-
sectional area (CSA) of muscle fibres (p ≤ 0.05), albeit not statistically different from 
HIT+β2A (Fig. 3e). Despite the induced hypertrophy of the thigh, maximal isometric muscle 
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strength (peak torque) of the quadriceps did not change in either HIT or HIT+β2A (Fig. 3g). 
In fact, when adjusting for adaptations in muscle fibre CSA, peak torque declined by 19% 
with the intervention in HIT (p ≤ 0.01), whereas no change was observed in HIT+β2A (Fig. 
3g). Likewise, peak twitch torque declined by 17% (p ≤ 0.05) and 27% (p ≤ 0.01) in HIT 
when unadjusted and adjusted for muscle fibre CSA, respectively, whereas non-significant 
increases were observed in HIT+β2A (Fig. 3h). Furthermore, muscle half-relaxation time was 
prolonged by 8 (± 6) ms with the intervention in HIT (p ≤ 0.05), but not differently from 
HIT+β2A that had no relevant change with the intervention (Fig. 3j). Degree of voluntary 
activation level (Fig. 3i), time-to-peak twitch torque (Fig. 3j) and rate of force development 
(Fig. 3k) of the quadriceps did not change in either group with the intervention. 
 
β2-agonist represses metabolic pathways 
Various myocellular pathways regulate substrate choice during exercise, where 
glycogenolysis and glycolysis are predominant metabolic pathways for glucose metabolism 
and β-oxidation for lipid metabolism. Though only minor changes were observed in proteins 
related to lipid metabolism, HIT and HIT+β2A had markedly diverse adaptations in the 
muscle proteome related to glycogenesis and glycogenolysis (Fig. 4a). Notably, in HIT+β2A, 
inhalation of β2-agonist attenuated the training-induced upregulation of glycogenin 1, 
glycogen debranching enzyme, glycogen synthase and glycogen phosphorylase observed in 
HIT (Table 6). HIT+β2A even had a marked downregulation of glycogen debranching 
enzyme, glycogen phosphorylase and glycogenin 1 (Fig. 4a, Table 5). Likewise, glycogen 
synthase, the rate-limiting enzyme in glycogenesis, which was the most significantly 
upregulated protein of the proteome in HIT (Fig. 4a, Table 2), did not change in HIT+β2A. 
For further confirmation of this observation, Western blotting of glycogen synthase revealed 
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a 25% increase in glycogen synthase abundance in HIT (p ≤ 0.01), which was blunted (p ≤ 
0.01) in HIT+β2A (Fig. 4d). In the glycolytic pathway, some minor changes were observed. 
Abundance of hexokinase 1 increased with the intervention in HIT+β2A compared to HIT 
(Table 4 and 6) with a concurrent minor repression of lactate dehydrogenase A chain (Table 
5). Partly in accordance with these observations, enzymatic analysis showed that maximal 
activity of hexokinase increased (p ≤ 0.01)(Fig. 4b) and lactate dehydrogenase decreased in 
HIT+β2A (p ≤ 0.05)(Fig. 4c). In contrast, HIT had a minor increase in abundance and 
maximal activity of the glycolytic rate-limiting enzyme, phosphofructokinase (p ≤ 0.05)(Fig. 
4b+d), and a marked increase in lactate dehydrogenase activity (p ≤ 0.01)(Fig. 4c). In 
general, principal component analysis revealed a good association between the different 
assays used to determine changes in glycogen synthase, hexokinase, phosphofructokinase and 
lactate dehydrogenase (Fig. 4f). 
 
The major sources of substrate for ATP production during endurance exercise are glucose 
and free fatty acids, whereas the contribution of amino acids is negligible (Jeukendrup & 
Wallis, 2005). As a measure for changes in substrate choice during exercise, we determined 
subjects’ glucose and fat oxidation by indirect calorimetry during steady state cycling both at 
same absolute intensity at 100 W and at an intensity corresponding to 60% of  ̇      before 
and after the intervention. While HIT had an increase in the relative contribution of glucose 
oxidation by 15.9 (± 7.0) percentage-points and a corresponding decline in fat oxidation with 
the intervention at both intensities (p ≤ 0.01), concomitant daily inhalation of β2-agonist 
blunted (p ≤ 0.05) this training-induced change in substrate choice in HIT+β2A (Fig. 4g). 
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Discussion 
Herein we have described adaptations in skeletal muscle proteome signature and phenotype 
induced by high intensity training with and without concomitant daily inhalation of β2-
agonist, as well as associated physiological adaptations in exercise performance,  ̇     , 
muscle contractile properties and substrate utilization during exercise. The most important 
findings were that daily β2-agonist treatment altered training-induced changes in muscle 
proteome signature and phenotype and attenuated enhancements in  ̇      and exercise 
performance. 
 
While several studies have investigated the effect of  high intensity interval training in human 
skeletal muscle (Laursen & Jenkens, 2002; Padrão et al. 2016; Hostrup & Bangsbo, 2017) 
and the chronic effect of β2-agonist treatment in rodent muscle (Pearen et al. 2009; Koopman 
et al. 2010), the present study is first to describe changes in muscle proteome signature and 
phenotype with related functional measures after an intervention with high intensity interval 
training and β2-agonist treatment in humans. Consistent with previous studies (Laursen & 
Jenkins, 2002; Milanovic et al. 2015), we observed that high intensity interval training 
effectively enhanced  ̇      and exercise performance in trained young men. More 
surprisingly, however, we observed that daily inhalation of β2-agonist, terbutaline, completely 
blunted training-induced increase in  ̇      and reduced enhancement in exercise 
performance. Although few studies in rodents have shown that systemic chronic treatment 
with β2-agonist clenbuterol blunts the effect of endurance training on exercise capacity 
(Ingalls et al. 1996; Duncan et al. 2000), the present study is first to show such effect of β2-
agonists in humans. Furthermore, the present study is first to show that daily β2-agonist 
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treatment attenuates the enhancing effect of endurance training on  ̇     . It is noteworthy 
that inhalation of  β2-agonist, in close to therapeutic doses, is capable of blunting the 
enhancing effects of high intensity interval training on  ̇      and exercise performance. 
This is possibly related to the relatively high systemic bioavailability of inhaled β2-agonists 
(Dyreborg et al. 2016), partitioning into muscle (Jacobson et al. 2014) and inducing a 
continuous adrenergic fight-or-flight response (Emrick et al. 2010; Andersson et al. 2012; 
Hostrup et al. 2014a). Accordingly, high inhalation of terbutaline has been shown to induce 
significant β2-adrenergic stimulation of skeletal muscle in humans (Hostrup et al. 2014a; 
Kalsen et al. 2016a; 2016b). The dosage of inhaled terbutaline (4 mg) administered in the 
present has also been shown to result in systemic concentrations that exceed those observed 
after oral administration of 10 mg terbutaline (Elers et al. 2012; Dyreborg et al. 2016).  
 
Our observations indicate that the attenuating effect of β2-agonist on training-induced 
enhancement in exercise performance and  ̇     , at least in part, may be related to 
remodelling of muscle proteome signature and phenotype. Indeed, enhancements in exercise 
performance and  ̇      observed in HIT were complemented by pronuonced upregulation 
of mitochondrial proteins and metabolic pathways in skeletal muscle, in particular related to 
oxidative phosphorylation and glycogen metabolism, being consistent with reports in humans 
and rodents (Holloway et al. 2009; Egan et al. 2011; Sollanek et al. 2017). In contrast, 
however, we observed that daily inhalation of β2-agonist attenuated training-induced 
upregulation of NADH dehydrogenase subcomplexes of the oxidative phosphorylation and 
even caused a repression of carbohydrate metabolic pathways, including downregulation of 
glycogen debranching enzyme, glycogen phosphorylase and glycogenin 1. The repressing 
effect of β2-agonist treatment on oxidative capacity and carbohydrate metabolism is in 
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agreement with observations in rodents (Torgan et al. 1995), in which chronic β2-agonist 
treatment has been shown to compromise mitochondrial function and pyruvate oxidation 
capacity (Hoshino et al. 2012). Given that a high capacity for oxidative metabolism and 
glycogenolysis is essential for energy and ion homeostasis of skeletal muscle and thus 
performance during intense exercise (Allen et al. 2008; Ørtenblad et al. 2013; Hostrup & 
Bangsbo, 2017), the attenuating effect of β2-agonist on training-induced upregulation of 
oxidative and glycogenolytic proteins may explain why training-induced enhancement in 
exercise performance was reduced in HIT+β2A. Furthermore, it may be speculated that β2-
agonist treatment compromised glycogen storage in HIT+β2A compared to HIT in the present 
study, since glycogenin 1 was repressed by β2-agonist treatment and that training-induced 
upregulation of glycogen synthase was blunted in HIT+β2A. Accordingly, expression and 
activity of glycogenin are proportional to glycogen content in human skeletal muscle (Shearer 
et al. 2000; Shearer et al. 2005) and glycogen synthase is a key enzyme in muscle 
glycogenesis (Bouskila et al. 2010). Thus, future studies should elucidate whether β2-agonist-
induced proteome changes in glycogen metabolism are associated with alterations in resting 
glycogen content and rate of glycogenolysis during exercise.  
 
Aside from the effect of β2-agonist treatment on training-induced adaptations in oxidative and 
metabolic pathways, we observed that terbutaline also modulated adaptations in muscle 
contractile phenotype and function. While the high intensity interval training regime 
undertaken induced a shift in muscle contractile phenotype from type IIx towards type IIa, 
concomitant daily inhalation of β2-agonist induced a muscle phenotype transition from slow- 
towards a fast-twitch phenotype. Although slow-to-fast-twitch muscle phenotype transition is 
a common phenomenon after chronic β2-agonist treatment in rodents (Dodd et al. 1996; 
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Zhang et al. 1996; Jones et al. 2004; Sirvent et al. 2014), this has not been described 
previously in humans. The contractile slow-to-fast twitch phenotype changes induced by 
chronic β2-agonist treatment have been shown to be associated with enhancements in 
maximal force and acceleration of relaxation time of skeletal muscle in both rodents and 
humans (Martineau et al. 1992; Dodd et al. 1996; Zhang et al. 1996; Hostrup et al. 2015; 
2016). On the contrary to these findings, however, β2-agonist treatment did not increase 
muscle force and peak twitch force or accelerate relaxation time of the quadriceps in 
HIT+β2A. This discrepancy is possibly related to the fact that β2-agonist treatment did not 
induce muscle hypertrophy or changes in expression of sarcoplasmic reticulum Ca
2+
 ATPase 
(SERCA) isoforms compared to placebo in the present study. As such, muscle hypertrophy 
has been shown to be the main mechanism by which chronic β2-agonist treatment enhances 
peak twitch and tetanic muscle force (Dodd et al. 1996; Hostrup et al. 2015). Furthermore, 
studies suggest that the accelerating effect of chronic β2-agonist treatment on muscle 
relaxation time is attributed to upregulation of SERCAI (Zhang et al. 1996; Hostrup et al. 
2015) and  concurrent downregulation of SERCAII and SERCA-regulatory subunit 
phospholamban (Zhang et al. 1996). In HIT, on the other hand, peak twitch force declined 
and relaxation time prolonged with the intervention, thus indicating that changes in 
contractile phenotype were associated with some of the adaptations in quadriceps contractile 
properties. Given that muscle contractile properties  are highly dependent on muscle fibre 
contractile phenotype (Harridge et al. 1996), the phenotype changes in HIT and HIT+β2A 
may explain why HIT had a slower muscle relaxation time and a decline in peak twitch 
torque after the intervention.  
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The observation that β2-agonist treatment alters training-induced remodelling of proteome 
signature and phenotype in relation to oxidative capacity as well as metabolic and contractile 
properties of skeletal muscle coincides with the acute and temporal changes in gene 
transcription profile observed in rodent skeletal muscle upon β2-adrenergic stimulation 
(Spurlock et al. 2006; Pearen et al. 2009). Acute β2-adrenoceptor activation has profound 
effects on global gene expression in rodent skeletal muscle, where β2-agonists formoterol and 
clenbuterol have been shown to enrich a variety of pathways, including those related to 
metabolism, cell-to-cell communication and transcriptional regulation (Spurlock et al. 2006; 
Pearen et al. 2009). Apart from the proteome adaptations in metabolism, we also observed 
that β2-agonist treatment induced an upregulation proteome pathways related to 
transcriptional regulation compared to training alone, including histone trimethylation and the 
nucleosome. Because β2-adrenergic stimulation induces an adrenergic fight-or-flight response 
in skeletal muscle (Emrick et al. 2010; Andersson et al. 2012), nucleosome adaptations to 
chronic β2-agonist treatment seem to be a logical consequence of the continuous adrenergic 
myocellular stress and signalling (Pearen et al. 2009). Indeed, non-selective β-agonist 
isoproterenol has been shown to induce expression of histones in cells (Lim & Juhnn, 2016), 
and Spurlock et al. (2006) observed that chronic β2-agonist treatment with clenbuterol 
upregulated transcriptional and translational initiator genes in rodent muscle. In addition, we 
observed that β2-agonist treatment upregulated proteome pathways related to adherens 
junction, cell-to-cell communication and cytoskeleton, inducing expression of actin and 
alpha-actinin 1 compared to training alone. It could be speculated that such upregulations 
may have impacted between-fibre force transfer positively in HIT+β2A (Nelson et al. 2016; 
Hughes et al. 2016; Lambert et al. 2016). Thus, a potential modulation of sarcomere 
architecture and cell-to-cell adhesion induced by β2-agonist treatment may explain why 
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HIT+β2A had no reduction in peak twitch torque and mass-specific peak torque compared to 
HIT. 
 
While the acute and chronic response to β2-adrenoceptor activation may have some 
similarities with exercise training (Spurlock et al. 2006; Pearen et al. 2009; Hostrup et al. 
2015), the present study, as well as studies in rodents (Ingalls et al. 1996; Lynch et al. 1996; 
Duncan et al. 2000; Mounier et al. 2007), indicate that chronic β2-agonist treatment 
confounds the effect of exercise training. For instance, although a common feature of chronic 
β2-agonist treatment is muscle hypertrophy in rodents and humans (Lynch & Ryall, 2008; 
Joassard et al. 2013; Hostrup et al. 2015), we observed no apparent induction of hypertrophy 
by β2-agonist treatment compared to training alone. This observation is consistent with 
observations in rodents, in which exercise training blunts or reduces the hypertrophic effect 
chronic clenbuterol treatment (Duncan et al. 2000; Mounier et al. 2007). The mechanisms 
underlying the attenuating effect of endurance training on the hypertrophic response to β2-
agonist treatment remain to be elucidated, but may be related to the fact that endurance 
training interferes with the growth-promoting signalling (Coffey & Hawley, 2017) induced 
upon β2-adrenergic stimulation (Koopman et al. 2010).  
 
In summary, the present study showed that daily inhalation of β2-agonist alters adaptations to 
four weeks of high intensity endurance training in recreationally active young men, both in 
terms of proteome signature remodelling and phenotype changes of skeletal muscle, but also 
in relation to functional adaptations in exercise performance,  ̇     , muscle contractile 
properties and substrate utilization during exercise. The most notably observation was that β2-
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agonist treatment attenuated training-induced enhancements in exercise performance and 
 ̇     , as well as blunted adaptations in oxidative phosphorylation and glycogen 
metabolism of skeletal muscle. Furthermore, that β2-agonist treatment induced a slow-to-fast 
twitch muscle fibre type transition. Future studies should elucidate the molecular mechanisms 
underlying the confounding effect of β2-agonist treatment on adaptations to endurance 
training. 
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Translational Perspective (word count: 249/250) 
This study tested the hypothesis that daily inhalation of β2-agonist alters adaptations in 
muscle proteome signature incurred from high intensity training. We observed that β2-agonist 
terbutaline blunted training-induced upregulation of proteome pathways related to oxidative 
phosphorylation and glycogen metabolism, while concurrently inducing a slow-to-fast twitch 
muscle phenotype transition. Notably, terbutaline also attenuated training-induced 
enhancements in  ̇      and exercise performance. These findings are of interest for the 
large proportion of persons using inhaled β2-agonists on a daily basis, including athletes, and 
indicate that athletes who have a high use of β2-agonist may benefit from lessening their 
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reliance on β2-agonist inhalers. This is also consistent with clinical guidelines, where regular 
reliance on β2-agonist is indicative of poor asthma control. Furthermore, the present study 
provides a fingerprint of some of the muscle proteome and phenotype changes induced by 
high intensity training with and without β2-agonist treatment, which may be used for future 
therapeutic applications. Indeed, it has long been proposed that β2-agonists have a therapeutic 
potential in treatment of muscle atrophic conditions (Lynch & Ryall, 2008; Joassard et al. 
2013), despite their potential cardiomyotoxic effects when administered in high doses. 
Accordingly, chronic β2-agonist treatment may repress oxidative capacity (Léger et al. 2011) 
and induce collagen infiltration and necrosis in rodent cardiac muscle (Duncan et al. 2000; 
Burniston et al. 2002; 2005; 2006; Gregorevic et al. 2005). Thus, the attenuating effect of 
daily β2-agonist treatment on training-induced enhancements in exercise performance and 
 ̇      may involve modulating effects in both skeletal and cardiac muscle. 
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Figure legends  
Fig. 1. Effect of four weeks of high intensity training with (HIT+β2A, n = 12) and without 
(HIT, n = 9) daily inhalation of terbutaline (4 mg/d) on proteome signature of the vastus 
lateralis muscle in trained men. a-c: Volcano plots of within-group changes in skeletal muscle 
proteins (486 proteins) in HIT (a) and HIT+β2A (b) as well as between-group interaction 
(HIT+β2A – HIT) (c). Green scale indicates %-false discovery rate (FDR). d: Gaussian fit of 
frequency distribution of discriminant canonical function score of within-group changes in 
proteome signature using principal component-discriminant analysis (PCA-DA) of the eight 
first principal components that explained 70% of total proteome variance. e-g: Enrichment 
analysis of the 10 most up- (blue) and downregulated (red) pathways (GO: biological 
processes, GO: cellular component, and KEGG pathways) in HIT (e) and HIT+β2A (f) as 
well as between-group (HIT+β2A – HIT) (g). 
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Fig. 2. Effect of four weeks of high intensity training with (HIT+β2A, n = 12) and without 
(HIT, n = 9) daily inhalation of terbutaline (4 mg/d) on outcomes related to exercise 
performance and oxidative capacity in trained men. a: Heat map of mean Z-score changes of 
the proteome related to tricarboxylate acid cycle and oxidative phosphorylation in HIT and 
HIT+β2A as well as between-group interaction (HIT+β2A   HIT). b: Mean (± 95%CI) 
maximal oxygen consumption ( ̇     )(left y-axis) and incremental peak power output 
(iPPO)(right y-axis). c: Mean (± 95%CI) relative change in  ̇      and iPPO when 
unadjusted and adjusted for thigh lean mass (TLM). d: Mean (± 95%CI) capillary density 
(left y-axis) and capillary-to-fiber ratio (right y-axis). e: Representative image of 
immunohistochemical analysis; myosin heavy chain I (red), IIa (green/brown), IIx (black), 
laminin (blue), capillary (light green). f: Mean (± 95%CI) expression (left y-axis) and 
maximal activity (right y-axis) of citrate synthase (CS). g: Bivariate correlation between 
intensity (log2-expression) of CS as determined by proteomics (y-axis) versus expression (left 
y-axis) and maximal activity (right y-axis) of CS as determined by Western blotting and 
fluorometrically, respectively. h: Mean (± 95%CI) relative change in abundance of OXPHOS 
complex I-V (CI-V) determined by Western blotting. i: Representative blots of CS and 
OXPHOS CI-V. 
#
Between-group interaction (p ≤ 0.05). ##Between-group interaction (p ≤ 
0.01). *Within-group difference from pre (p ≤ 0.05). **Within-group difference from pre (p ≤ 
0.01). 
  
 
This article is protected by copyright. All rights reserved. 
 
 
 
 
Fig. 3. Effect of four weeks of high intensity training with (HIT+β2A, n = 12) and without 
(HIT, n = 9) daily inhalation of terbutaline (4 mg/d) on outcomes related to contractile 
phenotype and function in trained men.  a: Heat map of mean Z-score changes of the 
proteome related to the cytoskeleton and contractile phenotype in HIT and HIT+β2A as well 
as between-group interaction (HIT+β2A   HIT). b: Gaussian fit of frequency distribution of 
discriminant canonical function score of within-group changes in the proteins listed in (a) 
using a principal component-discriminant analysis (PCA-DA) of the eight first principal 
components that explained 80% of the variance. c: Mean (± 95%CI) change in myosin heavy 
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chain (MHC) isoform distribution. d: PCA of intensity (log2-expression) of myosin isoforms 
determined by proteomics (white circles) and MHC isoform distribution determined 
immunohistochemically (purple circles). e-k: Mean (± 95%CI) values for muscle mass and 
contractile properties. CSA: cross-sectional area. 
#
Between-group interaction (p ≤ 0.05). 
##
Between-group interaction (p ≤ 0.01). *Within-group difference from pre (p ≤ 0.05). 
**Within-group difference from pre (p ≤ 0.01). 
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Fig. 4. Effect of four weeks of high intensity training with (HIT+β2A, n = 12) and without 
(HIT, n = 9) daily inhalation of terbutaline (4 mg/d) on outcomes related to metabolism in 
trained men. a: Heat map of mean Z-score changes of the proteome related to glycogenesis, 
glycogenolysis, glycolysis and lipid metabolism with the intervention in HIT and HIT+β2A as 
well as between-group interaction (HIT+β2A   HIT). b-c: Mean (± 95%CI) maximal activity 
for hexokinase (HK), phosphofructokinase (PFK) and lactate dehydrogenase (LDH). d: Mean 
(± 95%CI) relative change in abundance of GLUT4, glycogen synthase (GS) and PFK 
determined by Western blotting. e: Representative blots of GLUT4, GS and PFK. f: Principal 
component analysis of intensity (log2-expression) of GS, HK, LDHA, LDHB and PFK 
determined by proteomics (white circles), GS and PFK expression determined by Western 
blotting (yellow circles), and HK, LDH and PFK activity determined fluorumetrically (purple 
circles). g: Mean (± 95%CI) relative contribution of carbohydrate (COX)(red bars) and fat 
oxidation (FOX)(black bars) during cycling at 60% of maximal oxygen consumption 
( ̇     ) (left side) and at 100 W (right side). 
#
Between-group interaction (p ≤ 0.05). 
##
Between-group interaction (p ≤ 0.01). *Within-group difference from pre (p ≤ 0.05). 
**Within-group difference from pre (p ≤ 0.01). 
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Tables 
Table 1. Subject characteristics  
 HIT (n = 9) HIT+β2A (n = 12) Between-group 
difference (p-value) 
Age (years) 24.7 (± 3.0) 23.5 (± 1.7) 0.47 
Height (cm) 184 (± 3) 185 (± 2) 0.85 
Weight (kg) 78.4 (± 6.7) 77.6 (± 5.5) 0.86 
Lean body mass (kg) 61.5 (± 4.4) 60.6 (± 2.9) 0.72 
 ̇      (mL/min) 3932 (± 233) 3945 (± 329) 0.95 
MHCI (%) 49.4 (± 9.6) 49.2 (± 6.8) 0.97 
MHCIIa (%) 44.2 (± 9.4) 45.8 (± 5.9) 0.74 
MHCIIx (%) 6.5 (± 4.2) 5.0 (± 2.4) 0.46 
 ̇     : Maximal oxygen consumption. MHC: Myosin heavy chain. Values are mean (± 95% CI). 
Table 2. Upregulated proteins in HIT (n = 9) 
Name Description Log2-change 
q-
value 
GYS1 Glycogen [starch] synthase, muscle 0.46  
≤ 
0.01 
FUNDC2 FUN14 domain-containing protein 2 0.91  
≤ 
0.05 
NDUFA2 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 0.38  
≤ 
0.05 
COX6C Cytochrome c oxidase subunit 6C 0.63  
≤ 
0.05 
S100A13 Protein S100-A13 1.15  
≤ 
0.05 
DNAJA2 DnaJ homolog subfamily A member 2 1.00  
≤ 
0.05 
NDUFS6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial 0.54  
≤ 
0.05 
NDUFB6 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 0.51  
≤ 
0.05 
UQCRH Cytochrome b-c1 complex subunit 6, mitochondrial 0.36  
≤ 
0.05 
MRPL12 39S ribosomal protein L12, mitochondrial 1.04  
≤ 
0.05 
NDUFB3 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 0.40  
≤ 
0.05 
PHB Prohibitin 0.29  
≤ 
0.05 
B2M Beta-2-microglobulin;Beta-2-microglobulin form pI 5.3 0.97  
≤ 
0.05 
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ATP5H ATP synthase subunit d, mitochondrial 0.28  
≤ 
0.05 
SSBP1 Single-stranded DNA-binding protein, mitochondrial 0.22  
≤ 
0.05 
MYOZ2 Myozenin-2 0.48  
≤ 
0.05 
NDUFV2 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial 0.28  
≤ 
0.05 
STOML2 Stomatin-like protein 2, mitochondrial 0.43  
≤ 
0.05 
ATP5J ATP synthase-coupling factor 6, mitochondrial 0.35  
≤ 
0.05 
COX5A Cytochrome c oxidase subunit 5A, mitochondrial 0.24  
≤ 
0.05 
PLIN2 Perilipin-2 0.39  
≤ 
0.05 
NDUFB8 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial 0.55  
≤ 
0.05 
SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 0.14  
≤ 
0.05 
CHCHD3 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial 0.30  
≤ 
0.05 
AGL Glycogen debranching enzyme;4-alpha-glucanotransferase;Amylo-alpha-1,6-glucosidase 0.23  
≤ 
0.05 
IMMT Mitochondrial inner membrane protein 0.20  
≤ 
0.05 
 
Table 3. Downregulated proteins in HIT (n = 9) 
Name Description Log2-change q-value 
PARK7 Protein DJ-1 -0.25  ≤ 0.05 
MYBPC1 Myosin-binding protein C, slow-type -0.23  ≤ 0.05 
MYH1 Myosin-1 -0.48  ≤ 0.05 
PNPO Pyridoxine-5-phosphate oxidase -0.31  ≤ 0.05 
FKBP3 Peptidyl-prolyl cis-trans isomerase FKBP3 -0.25  ≤ 0.05 
HSPB1 Heat shock protein beta-1 -0.19  ≤ 0.05 
 
Table 4. Upregulated proteins in HIT+β2A (n = 12) 
Name Description Log2-change q-value 
S100A13 Protein S100-A13 1.80  ≤ 0.001 
ACTG1 Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed 0.97  ≤ 0.001 
B2M Beta-2-microglobulin;Beta-2-microglobulin form pI 5.3 1.22  ≤ 0.01 
PADI2 Protein-arginine deiminase type-2 0.41  ≤ 0.01 
SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 0.25  ≤ 0.01 
AHNAK Neuroblast differentiation-associated protein AHNAK 0.44  ≤ 0.01 
PCBP1 Poly(rC)-binding protein 1 0.49  ≤ 0.01 
EEF1A1P5;EEF1A1 Putative elongation factor 1-alpha-like 3;Elongation factor 1-alpha 1 1.96  ≤ 0.01 
HK1 Hexokinase-1 0.47  ≤ 0.01 
YWHAZ 14-3-3 protein zeta/delta 0.27  ≤ 0.01 
ACSL1 Long-chain-fatty-acid--CoA ligase 1 0.35  ≤ 0.01 
PACSIN3 Protein kinase C and casein kinase substrate in neurons protein 3 0.24  ≤ 0.01 
S100A6 Protein S100-A6 0.68  ≤ 0.01 
DES Desmin 0.39  ≤ 0.05 
ACTR3 Actin-related protein 3 0.40  ≤ 0.05 
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RPL5 60S ribosomal protein L5 0.31  ≤ 0.05 
STOML2 Stomatin-like protein 2, mitochondrial 0.49  ≤ 0.05 
HSPA5 78 kDa glucose-regulated protein 0.30  ≤ 0.05 
MAPT Microtubule-associated protein tau 0.40  ≤ 0.05 
ANP32A Acidic leucine-rich nuclear phosphoprotein 32 family member A 1.58  ≤ 0.05 
RPSA 40S ribosomal protein SA 0.43  ≤ 0.05 
PDIA6 Protein disulfide-isomerase A6 0.59  ≤ 0.05 
HNRNPK Heterogeneous nuclear ribonucleoprotein K 0.37  ≤ 0.05 
MYL9 Myosin regulatory light polypeptide 9 0.87  ≤ 0.05 
PPP1R14B Protein phosphatase 1 regulatory subunit 14B 0.52  ≤ 0.05 
TOM1 Target of Myb protein 1 0.31  ≤ 0.05 
HADHA Trifunctional enzyme subunit alpha, mitochondrial 0.32  ≤ 0.05 
NDUFC2 NADH dehydrogenase [ubiquinone] 1 subunit C2 0.73  ≤ 0.05 
TIMM50 Mitochondrial import inner membrane translocase subunit TIM50 0.69  ≤ 0.05 
NDUFS1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 0.33  ≤ 0.05 
ACTC1 Actin, alpha cardiac muscle 1 1.21  ≤ 0.05 
PFN1 Profilin-1 0.25  ≤ 0.05 
MAOB Amine oxidase [flavin-containing] B 0.59  ≤ 0.05 
MYL6 Myosin light polypeptide 6 0.96  ≤ 0.05 
 
 
Table 5. Downregulated proteins in HIT+β2A (n = 12) 
Name Description Log2-change q-value 
HSPB1 Heat shock protein beta-1 -0.49  ≤ 0.001 
ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase -0.25  ≤ 0.001 
GYG1 Glycogenin-1 -0.62  ≤ 0.001 
CFL2 Cofilin-2 -0.36  ≤ 0.001 
FHL1 Four and a half LIM domains protein 1 -0.31  ≤ 0.001 
PTGR2 Prostaglandin reductase 2 -0.36  ≤ 0.001 
CRYAB Alpha-crystallin B chain -0.30  ≤ 0.01 
HSPA2 Heat shock-related 70 kDa protein 2 -0.35  ≤ 0.01 
GSTM2 Glutathione S-transferase Mu 2 -0.30  ≤ 0.01 
ST13 Hsc70-interacting protein -0.22  ≤ 0.01 
CMBL Carboxymethylenebutenolidase homolog -0.32  ≤ 0.01 
HSPB7 Heat shock protein beta-7 -0.33  ≤ 0.01 
DNPEP Aspartyl aminopeptidase -0.28  ≤ 0.01 
ACO1 Cytoplasmic aconitate hydratase -0.25  ≤ 0.01 
AGL Glycogen debranching enzyme -0.32  ≤ 0.01 
MACROD1 O-acetyl-ADP-ribose deacetylase MACROD1 -0.20  ≤ 0.01 
PSMA6 Proteasome subunit alpha type-6 -0.23  ≤ 0.01 
PSMB3 Proteasome subunit beta type-3 -0.32  ≤ 0.01 
NDRG2 Protein NDRG2 -0.23  ≤ 0.01 
MDH1 Malate dehydrogenase, cytoplasmic -0.23  ≤ 0.01 
CUTC Copper homeostasis protein cutC homolog -0.42  ≤ 0.05 
PDLIM5 PDZ and LIM domain protein 5 -0.23  ≤ 0.05 
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CAB39 Calcium-binding protein 39 -0.26  ≤ 0.05 
NDUFB7 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 -0.54  ≤ 0.05 
PREP Prolyl endopeptidase -0.24  ≤ 0.05 
TPM3 Tropomyosin alpha-3 chain -0.41  ≤ 0.05 
WDR1 WD repeat-containing protein 1 -0.18  ≤ 0.05 
LMCD1 LIM and cysteine-rich domains protein 1 -0.29  ≤ 0.05 
PSMA5 Proteasome subunit alpha type-5 -0.24  ≤ 0.05 
TNNC1 Troponin C, slow skeletal and cardiac muscles -0.30  ≤ 0.05 
MAPRE2 Microtubule-associated protein RP/EB family member 2 -0.44  ≤ 0.05 
YWHAG 14-3-3 protein gamma;14-3-3 protein gamma, N-terminally processed -0.20  ≤ 0.05 
TXLNB Beta-taxilin -0.24  ≤ 0.05 
PYGM Glycogen phosphorylase, muscle form -0.31  ≤ 0.05 
LDB3 LIM domain-binding protein 3 -0.17  ≤ 0.05 
TPM2 Tropomyosin beta chain -0.44  ≤ 0.05 
AMPD1 AMP deaminase 1 -0.33  ≤ 0.05 
LMNB2 Lamin-B2 -0.84  ≤ 0.05 
ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial -0.27  ≤ 0.05 
PRDX1 Peroxiredoxin-1 -0.17  ≤ 0.05 
CRYZ Quinone oxidoreductase -0.26  ≤ 0.05 
TPT1 Translationally-controlled tumor protein -0.17  ≤ 0.05 
PHPT1 14 kDa phosphohistidine phosphatase -0.16  ≤ 0.05 
PFN2 Profilin-2 -0.99  ≤ 0.05 
MYOM2 Myomesin-2 -0.21  ≤ 0.05 
NPEPPS Puromycin-sensitive aminopeptidase -0.17  ≤ 0.05 
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 -0.29  ≤ 0.05 
PCBD2 Pterin-4-alpha-carbinolamine dehydratase 2 -0.34  ≤ 0.05 
LDHA L-lactate dehydrogenase A chain -0.19  ≤ 0.05 
NT5C1A Cytosolic 5-nucleotidase 1A -0.46  ≤ 0.05 
PARK7 Protein DJ-1 -0.15  ≤ 0.05 
 
Table 6. Between-group interaction (HIT+β2A – HIT) 
Name Description Log2-change q-value 
GYG1 Glycogenin-1 -0.67  ≤ 0.01 
HSPB7 Heat shock protein beta-7 -0.53  ≤ 0.01 
AGL Glycogen debranching enzyme -0.55  ≤ 0.01 
ACTG1 Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed 0.94  ≤ 0.01 
FHL1 Four and a half LIM domains protein 1 -0.31  ≤ 0.01 
CFL2 Cofilin-2 -0.31  ≤ 0.01 
GYS1 Glycogen [starch] synthase, muscle -0.52  ≤ 0.01 
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 -0.59  ≤ 0.05 
TNNC1 Troponin C, slow skeletal and cardiac muscles -0.50  ≤ 0.05 
CRYAB Alpha-crystallin B chain -0.31  ≤ 0.05 
ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase -0.17  ≤ 0.05 
ACO1 Cytoplasmic aconitate hydratase -0.28  ≤ 0.05 
NDUFS6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial -0.68  ≤ 0.05 
TPM3 Tropomyosin alpha-3 chain -0.62  ≤ 0.05 
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PYGM Glycogen phosphorylase, muscle form -0.50  ≤ 0.05 
LDB3 LIM domain-binding protein 3 -0.26  ≤ 0.05 
MRPS36 28S ribosomal protein S36, mitochondrial -0.44  ≤ 0.05 
PSMB3 Proteasome subunit beta type-3 -0.37  ≤ 0.05 
NDUFB6 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 -0.57  ≤ 0.05 
NDUFB7 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 -0.64  ≤ 0.05 
HSPB1 Heat shock protein beta-1 -0.29  ≤ 0.05 
HIST1H1C;HIST1H1E 
HIST1H1D Histone H1.2;Histone H1.4;Histone H1.3 0.51  ≤ 0.05 
LMCD1 LIM and cysteine-rich domains protein 1 -0.39  ≤ 0.05 
SSBP1 Single-stranded DNA-binding protein, mitochondrial -0.27  ≤ 0.05 
ACTN1 Alpha-actinin-1 0.61  ≤ 0.05 
AHNAK Neuroblast differentiation-associated protein AHNAK 0.43  ≤ 0.05 
MRPL12 39S ribosomal protein L12, mitochondrial -1.23  ≤ 0.05 
TPM2 Tropomyosin beta chain -0.62  ≤ 0.05 
HK1 Hexokinase-1 0.44  ≤ 0.05 
YWHAZ 14-3-3 protein zeta/delta 0.28  ≤ 0.05 
NDUFA2 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 -0.30  ≤ 0.05 
KPNB1 Importin subunit beta-1 0.71  ≤ 0.05 
 
 
